‘Enhancing Sexual Performance with Stem Cell Therapy’ Available for Playback
SUNRISE, FL – Feb. 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has posted a live playback of its Saturday webinar here, “Enhancing Sexual Performance with Stem Cell Therapy” — an informative Q & A with USRM Chief Science Officer Dr. Kristin Comella and leading biohacker and CEO of health company Kion, Ben Greenfield, who recently had penile stem cell injections to enhance sexual performance.
Greenfield, who recently received stromal vascular fraction treatments (SVF) intravenously for overall bioenhancement, as well as penile injections for erectile enhancement, says as a result of the treatments his overall healing function as well as sexual performance has been significantly enhanced.
“I’ve done IV stem cells as well as knee and hip joint. It took about 5 to 7 days to kick in. I went from being laid up and injured to almost being 100% ready for race season,” says Greenfield, who regularly participates in Ironman and other endurance races. Regarding autologous, IV stem cell injections, Greenfield stated “It’s a huge increase in energy… a clear head, less of a need to nap in the afternoon, better workouts and workout recovery — an improved overall sense of well-being. With penis injection … it took about 3 to 4 days to kick in and the main things I noticed were significant increase in erectile function, a significant increase in size in what we call ‘at rest,’ better orgasms, better blood flow — the anatomical manifestations cannot be denied.”
“Ben’s experience is a perfect example of someone who is using stem cell therapy proactively, to enhance physical performance at a very high level,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “His testimony is a terrific way for patients interested in learning more about the process to get a front row seat, even in the playback the questions and answers can be beneficial for those who are interested in the process.”
SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.
Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.
“Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy. The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live Feb. 9, can be accessed as a playback here.
Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.